/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
Aegon calls USD 500 million in perpetual capital securities
THE HAGUE, Netherlands–(BUSINESS WIRE)–Aegon today announces that it is exercising its right to redeem the USD
500 million perpetual capital securities with a coupon of 6.5% issued in
2005. The redemption of these grandfathered Tier 1 securities will be
effective June 15, 2019, when the principal amount of USD 500 million
will be repaid together with any accrued and unpaid interest.
The securities (ISIN code: NL0000062420, CUSIP code: N007924400) are
currently listed on the New York Stock Exchange with symbol AED. This
listing will be terminated following the redemption of the securities.
A notice of redemption will be sent to all currently registered holders
of the subordinated notes by the trustee, The Bank of New York Mellon.
The Paying Agent is Citibank N.A., 480 Washington Boulevard, 30th Floor,
Jersey City, New Jersey 07310.
This press release does not constitute a notice of redemption of the
subordinated notes.
About Aegon
Aegon’s roots go back 175 years – to the first half of the nineteenth
century. Since then, Aegon has grown into an international company, with
businesses in more than 20 countries in the Americas, Europe and Asia.
Today, Aegon is one of the world’s leading financial services
organizations, providing life insurance, pensions and asset management.
Aegon’s purpose is to help people achieve a lifetime of financial
security. More information on aegon.com.
Disclaimers
Forward-looking statements
The statements contained in this document that are not historical facts
are forward-looking statements as defined in the US Private Securities
Litigation Reform Act of 1995. The following are words that identify
such forward-looking statements: aim, believe, estimate, target, intend,
may, expect, anticipate, predict, project, counting on, plan, continue,
want, forecast, goal, should, would, could, is confident, will, and
similar expressions as they relate to Aegon. These statements are not
guarantees of future performance and involve risks, uncertainties and
assumptions that are difficult to predict. Aegon undertakes no
obligation to publicly update or revise any forward-looking statements.
Readers are cautioned not to place undue reliance on these
forward-looking statements, which merely reflect company expectations at
the time of writing. Actual results may differ materially from
expectations conveyed in forward-looking statements due to changes
caused by various risks and uncertainties. Such risks and uncertainties
include but are not limited to the following:
-
Changes in general economic and/or governmental conditions,
particularly in the United States, the Netherlands and the United
Kingdom; -
Changes in the performance of financial markets, including emerging
markets, such as with regard to:-
The frequency and severity of defaults by issuers in Aegon’s fixed
income investment portfolios; -
The effects of corporate bankruptcies and/or accounting
restatements on the financial markets and the resulting decline in
the value of equity and debt securities Aegon holds; and -
The effects of declining creditworthiness of certain public sector
securities and the resulting decline in the value of government
exposure that Aegon holds;
-
The frequency and severity of defaults by issuers in Aegon’s fixed
-
Changes in the performance of Aegon’s investment portfolio and decline
in ratings of Aegon’s counterparties; -
Consequences of an actual or potential break-up of the European
monetary union in whole or in part; -
Consequences of the anticipated exit of the United Kingdom from the
European Union and potential consequences of other European Union
countries leaving the European Union; - The frequency and severity of insured loss events;
-
Changes affecting longevity, mortality, morbidity, persistence and
other factors that may impact the profitability of Aegon’s insurance
products; -
Reinsurers to whom Aegon has ceded significant underwriting risks may
fail to meet their obligations; -
Changes affecting interest rate levels and continuing low or rapidly
changing interest rate levels; -
Changes affecting currency exchange rates, in particular the EUR/USD
and EUR/GBP exchange rates; -
Changes in the availability of, and costs associated with, liquidity
sources such as bank and capital markets funding, as well as
conditions in the credit markets in general such as changes in
borrower and counterparty creditworthiness; -
Increasing levels of competition in the United States, the
Netherlands, the United Kingdom and emerging markets; -
Changes in laws and regulations, particularly those affecting Aegon’s
operations’ ability to hire and retain key personnel, taxation of
Aegon companies, the products Aegon sells, and the attractiveness of
certain products to its consumers; -
Regulatory changes relating to the pensions, investment, and insurance
industries in the jurisdictions in which Aegon operates; -
Standard setting initiatives of supranational standard setting bodies
such as the Financial Stability Board and the International
Association of Insurance Supervisors or changes to such standards that
may have an impact on regional (such as EU), national or US federal or
state level financial regulation or the application thereof to Aegon,
including the designation of Aegon by the Financial Stability Board as
a Global Systemically Important Insurer (G-SII); -
Changes in customer behavior and public opinion in general related to,
among other things, the type of products Aegon sells, including legal,
regulatory or commercial necessity to meet changing customer
expectations; - Acts of God, acts of terrorism, acts of war and pandemics;
- Changes in the policies of central banks and/or governments;
-
Lowering of one or more of Aegon’s debt ratings issued by recognized
rating organizations and the adverse impact such action may have on
Aegon’s ability to raise capital and on its liquidity and financial
condition; -
Lowering of one or more of insurer financial strength ratings of
Aegon’s insurance subsidiaries and the adverse impact such action may
have on the premium writings, policy retention, profitability and
liquidity of its insurance subsidiaries; -
The effect of the European Union’s Solvency II requirements and other
regulations in other jurisdictions affecting the capital Aegon is
required to maintain; -
Litigation or regulatory action that could require Aegon to pay
significant damages or change the way Aegon does business; -
As Aegon’s operations support complex transactions and are highly
dependent on the proper functioning of information technology,
operational risks such as system disruptions or failures, security or
data privacy breaches, cyberattacks, human error, failure to safeguard
personally identifiable information, changes in operational practices
or inadequate controls including with respect to third parties with
which we do business may disrupt Aegon’s business, damage its
reputation and adversely affect its results of operations, financial
condition and cash flows; - Customer responsiveness to both new products and distribution channels;
-
Competitive, legal, regulatory, or tax changes that affect
profitability, the distribution cost of or demand for Aegon’s products; -
Changes in accounting regulations and policies or a change by Aegon in
applying such regulations and policies, voluntarily or otherwise,
which may affect Aegon’s reported results, shareholders’ equity or
regulatory capital adequacy levels; -
Aegon’s projected results are highly sensitive to complex mathematical
models of financial markets, mortality, longevity, and other dynamic
systems subject to shocks and unpredictable volatility. Should
assumptions to these models later prove incorrect, or should errors in
those models escape the controls in place to detect them, future
performance will vary from projected results; -
The impact of acquisitions and divestitures, restructurings, product
withdrawals and other unusual items, including Aegon’s ability to
integrate acquisitions and to obtain the anticipated results and
synergies from acquisitions; -
Catastrophic events, either manmade or by nature, could result in
material losses and significantly interrupt Aegon’s business; and -
Aegon’s failure to achieve anticipated levels of earnings or
operational efficiencies as well as other cost saving and excess cash
and leverage ratio management initiatives.
This press release contains information that qualifies, or may qualify,
as inside information within the meaning of Article 7(1) of the EU
Market Abuse Regulation (596/2014). Further details of potential risks
and uncertainties affecting Aegon are described in its filings with the
Netherlands Authority for the Financial Markets and the US Securities
and Exchange Commission, including the Annual Report. These
forward-looking statements speak only as of the date of this document.
Except as required by any applicable law or regulation, Aegon expressly
disclaims any obligation or undertaking to release publicly any updates
or revisions to any forward-looking statements contained herein to
reflect any change in Aegon’s expectations with regard thereto or any
change in events, conditions or circumstances on which any such
statement is based.
Contacts
Media relations
Dick Schiethart
+31(0) 70 344 8821
[email protected]
Investor relations
Jan Willem Weidema
+31(0) 70 344 8028
[email protected]
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493
Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493
Cannabis
Sannabis, Inc. (OTC: USPS) Announces First Shipment of Cannabis Essential Oil from Colombia to U.S. to Fill First Order, as the DEA Re-Classifies Marijuana from Schedule I to Schedule III
Humboldt
Humboldt Seed Company partners with Apollo Green to bring California cannabis genetics to the global marketplace
Apollo Green to distribute Humboldt Seed Company clonal cannabis genetics to Germany, Portugal and Australia
SAN FRANCISCO, April 30, 2024 /PRNewswire/ — Humboldt Seed Company (HSC), California’s leading cannabis seed producer, has announced a partnership with Canadian-based Apollo Green to make eight breeder cuts available to researchers, licensed commercial cultivators and home growers in legal markets worldwide. This first-to-market clonal genetics release is a significant milestone and will expand access to distinctive, high-quality cannabis genetics in both established and emerging global markets including Germany, Portugal and Australia.
The curated, breeder-verified selection includes pioneering triploid genetics, such as OG Triploid and Donutz Triploid alongside the legendary cult classic Blueberry Muffin. Also available are All Gas OG with a THC content of 21% and four high-THC strains in the 30-35% range: Golden Sands, Guzzlerz, Jelly Donutz and Orange Creampop. These selections represent the top .01% from HSC’s extensive California pheno-hunting program.
Exports will begin in May under Apollo Green’s Canadian federal cannabis license. All shipments have Canadian phytosanitary certification, ensuring plants have been inspected, and are clean and free of pests.
“Access for all to quality genetics has been our core focus since the beginning,” said HSC Co-founder and Chief Science Officer, Benjamin Lind. “Our science-based approach to breeding aligns perfectly with Apollo Green’s high standards and we are excited to be able to extend these hand-selected cuts to a wider audience, especially at this pivotal time where we’re seeing positive regulatory changes globally.”
Oisin Tierney, Apollo Green Director of Business Development, said, “California has long been recognized for setting industry standards, and we are proud to play a role in bringing these esteemed genetics to cultivators worldwide. The triploids are especially noteworthy in terms of the unprecedented potential for enhanced plant vigor, higher yields, shorter flowering times and superior returns for solventless extraction.”
About Humboldt Seed Company
Established in 2001, Humboldt Seed Company is a Northern California heritage brand providing quality cannabis genetics to commercial cultivators and home growers in legalized states across the U.S. and international markets including Spain, Canada, Jamaica, South Africa, Colombia, France, Portugal, Greece, the UK, Malta and Thailand. With a focus on environmental and social justice, they combine traditional breeding and modern scientific practices in their strain development program. They have served the cannabis community for over two decades.
For more information visit https://humboldtseedcompany.com/.
About Apollo Green
Licensed since 2019, Apollo Green is Canada’s leader in cannabis genetics. The company’s mission is to provide an ever-growing bank of seeds and clones to medical patients and recreational consumers. Apollo Green provides clean, trusted cannabis seeds and clones, which are backed by the foremost tissue culture technology to reduce risks, costs and time-to-market for licensed producers around the world. Apollo Green is passionate about cannabis genetics.
For more information visit https://apollogreen.com/.
Media contact
Jaana Prall
[email protected]
Logo – https://mma.prnewswire.com/media/2328955/Humboldt_Seed_Company_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/humboldt-seed-company-partners-with-apollo-green-to-bring-california-cannabis-genetics-to-the-global-marketplace-302131618.html
Cannabis
Technological Advancements in Breathalyzers Drive Market Growth and Enhance Road Safety
-
Cannabis2 weeks ago
Sannabis, Inc. (OTC: USPS) Unveils Innovative NO LICK! Terpene Spray for Cannabis Products to Enhance CBD and THC to Achieve the Entourage Effect
-
Cannabis2 weeks ago
Cannabis Concentrate Market to Cross US$2.4 Billion by 2030 amid Rising Medical and Recreational Demand
-
Innocan1 week ago
Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain
-
Curaleaf1 week ago
Curaleaf Completes Acquisition of Northern Green Canada
-
Cannabis1 week ago
Cannabis Capsule Global Analysis Report 2024: Market to Reach $79.2 Billion in 2028 – Forecast to 2033 Featuring GW Pharmaceuticals, Trulieve Cannabis, Green Thumb Industries, Tilray, Columbia Care
-
SCHWAZZE3 days ago
Schwazze Sets First Quarter 2024 Conference Call for May 15, 2024 at 5:00 p.m. ET
-
Cannabis2 days ago
Technological Advancements in Breathalyzers Drive Market Growth and Enhance Road Safety
-
Humboldt2 days ago
Humboldt Seed Company partners with Apollo Green to bring California cannabis genetics to the global marketplace